Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbing Qiu

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Sensors (Basel, Switzerland)|June 19, 2020
LDPC-Coded CAP with Spatial Diversity for UVLC Systems over Generalized-Gamma Fading ChannelHongyan Jiang, Hongbing Qiu, Ning He, et al.
Sensors (Basel, Switzerland)|November 14, 2023
Indoor Human Action Recognition Based on Dual Kinect V2 and Improved Ensemble Learning MethodRuixiang Kan, Hongbing Qiu, Xin Liu, et al.
BMB Reports|February 28, 2024
Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
BMB Reports|January 8, 2023
circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
BMB Reports|July 27, 2023
Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
International Journal of Clinical and Experimental Medicine|July 30, 2015
Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cellsZhengmao Zhang, Zhen Xie, Guangyu Sun, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 6, 2016
Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatmentLijun Qin, Hongbing Qiu, Minjie Zhang, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Sensors (Basel, Switzerland)|June 19, 2020
LDPC-Coded CAP with Spatial Diversity for UVLC Systems over Generalized-Gamma Fading ChannelHongyan Jiang, Hongbing Qiu, Ning He, et al.
Sensors (Basel, Switzerland)|November 14, 2023
Indoor Human Action Recognition Based on Dual Kinect V2 and Improved Ensemble Learning MethodRuixiang Kan, Hongbing Qiu, Xin Liu, et al.
BMB Reports|February 28, 2024
Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
BMB Reports|January 8, 2023
circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
BMB Reports|July 27, 2023
Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axisKaiyun Qin, Fenghua Zhang, Hongxia Wang, et al.
International Journal of Clinical and Experimental Medicine|July 30, 2015
Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cellsZhengmao Zhang, Zhen Xie, Guangyu Sun, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 6, 2016
Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatmentLijun Qin, Hongbing Qiu, Minjie Zhang, et al.
Pageof 2